Read this article to learn about guidance for care at and after a death, and the bereavement support offered to the family.

The US Food and Drug Administration has issued guidance urging sponsors and trial sites to consider the necessity of the invasive procedure.

The agency is proposing that device manufacturers improve their testing to including larger, more diverse sample sizes.

During the international meeting, experts from across the region will present new and updated NCCN Clinical Practice ...

As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The U.S. Food and Drug Administration (FDA) recently announced final guidance for firms in the medical device and product industry ...

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective ...

These areas of potential improvement are characterized by common assumptions about how clinical healthcare ... tool to legislate practice or set reimbursement policies. [12] Otherwise, declining ...

A new systematic literature search identified the highest priority clinical actions aimed at improving post-acute care for ...

Experts say the primary care workforce is well suited to meet patients’ contraceptive needs but the numbers of primary care ...